Patent ID: 8916342

Claim:
A method for determining a disease stage of human papillomavirus (HPV) infection in a human subject comprising: contacting a tissue sample or a cell sample with a first one or more monoclonal antibodies, wherein the tissue sample or the cell sample comprises protein, and the sample is obtained from a human subject; the first one or more monoclonal antibodies specifically bind to two or more viral proteins, and the one or more monoclonal antibodies are capable of binding in situ to the viral proteins in the tissue sample or the cell sample, wherein the viral proteins comprise two or more HPV E6 proteins from different HPV types in a clinical sample and/or two or more HPV E7 proteins from different HPV types in a clinical sample; and said contacting takes place under conditions that promote specific binding of said one or more monoclonal antibodies; contacting the tissue sample or the cell sample with a second one or more antibodies that specifically binds to a cellular protein; determining presence, absence, or an amount of the two or more viral proteins in said sample that specifically binds to the first one or more monoclonal antibodies based at least in part on a measure of specific binding of the first one or more monoclonal antibodies to the sample contacted by the one or more monoclonal antibodies; determining presence, absence, or an amount of the cellular protein in said sample that specifically binds to the second one or more antibodies based at least in part on a measure of specific binding of the second one or more antibodies to the sample contacted by the second one or more antibodies; and determining said disease stage of papillomavirus infection in said human subject based on said determined presence, absence, or amount of the viral proteins and the cellular protein in said sample.